Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice looking Monday morning here... hopes you are in good form Hunch.... love seeing premarket double digit green... best of luck to all OGI investors.....
Bought in here in seven seventies on Friday, hoping good news is not far off.
thanks for your wonderful words...
I am glad I got in here at 7.13.... however, like all of us, I should have bought more.... lol
Thanks for your updates.... I'm dipping my toes in here...
Hexo flying in premarket... up 36%....
Last July: Tilray Brands acquired the HEXO Note from HTI, which has a current principal balance of $173.7 million outstanding
Cannabis stocks extended recent gains to stage a rally towards the market close on Friday after President Joe Biden signed a marijuana research bill into law.
Notable gainers include Clever Leaves (CLVR), SNDL Inc. (SNDL), MedMen Enterprises (OTCQB:MMNFF), Canopy Growth Corporation (CGC), Tilray Brands (NASDAQ:TLRY), TerrAscend Corp. (OTCQX:TCNNF), OrganiGram Holdings (OGI), Aurora Cannabis (ACB), GrowGeneration (GRWG) and Cronos Group (CRON)
The bill named Medical Marijuana and Cannabidiol Research Expansion Act cleared the House in April and the Senate last month.
It establishes a new registration process for cannabis-related research and the production of marijuana for research and drug development.
https://seekingalpha.com/news/3913664-tlry-stock-sndl-stock-lead-cannabis-stocks-higher-as-biden-signs-marijuana-law?mailingid=29873306&messageid=2900&serial=29873306.8691&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=29873306.8691
Cannabis stocks extended recent gains to stage a rally towards the market close on Friday after President Joe Biden signed a marijuana research bill into law.
Notable gainers include Clever Leaves (CLVR), SNDL Inc. (SNDL), MedMen Enterprises (OTCQB:MMNFF), Canopy Growth Corporation (CGC), Tilray Brands (NASDAQ:TLRY), TerrAscend Corp. (OTCQX:TCNNF), OrganiGram Holdings (OGI), Aurora Cannabis (ACB), GrowGeneration (GRWG) and Cronos Group (CRON)
The bill named Medical Marijuana and Cannabidiol Research Expansion Act cleared the House in April and the Senate last month.
It establishes a new registration process for cannabis-related research and the production of marijuana for research and drug development.
https://seekingalpha.com/news/3913664-tlry-stock-sndl-stock-lead-cannabis-stocks-higher-as-biden-signs-marijuana-law?mailingid=29873306&messageid=2900&serial=29873306.8691&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=29873306.8691
Now that the UK (politically lead by Mitch McConnell supporters) is out of Europe, pressure is building with progressives across the old continent to legalise cannabis... The majority of Europeans now realise that the war on drugs, and especially cannabis prohibition, were some of the worst decisions made by human fools....
This is good news going forward for Tilray investors, especially with steady legalisation moves in Germany. What old farts wish not to recognise is that we Europeans all live in democracies, meaning: the will of the people, and most of the majorities in EU countries desire to end prohibition.
Here's some more news from Germany:
https://internationalcbc.com/german-lawmakers-call-for-cannabis-legalization-bill-to-be-expedited/
Yep, Hunch, looking good... a great wee investment here....
yes, Mike, you are correct.... running good (up 9% todate) for '23.... hopes you make money with this fab company...
OGI Revenue beats by $13.45M.
Organigram reports Q4 results; issues FY23 soft guidance
Nov. 29, 2022 OrganiGram Holdings Inc. (OGI),
Organigram press release (NASDAQ:OGI):
Q4 net loss was $6.1M, compared to a net loss of $26.0M in Q4 Fiscal 2021.
Adjusted EBITDA of $3.2M, the third consecutive quarter of positive Adjusted EBITDA, compared to negative Adjusted EBITDA of $4.8M in the same prior year period.
Adjusted Gross Margin of $10.4M or 23%, compared to $3.0M or 12% in the same prior year period, reflecting improvements from increased efficiencies and higher sales volume.
Revenue of $45.5M (+82.7% Y/Y) beats by $13.45M.
Outlook: Organigram currently expects Fiscal 2023 revenue to be higher than that of Fiscal 2022.
The company expects to see an improvement in adjusted gross margins in Fiscal 2023 and has put measures in place that it expects will further improve margins over time.
The company expects significant growth in Adjusted EBITDA in Fiscal 2023 over Fiscal 2022.
The company expects to have positive cash flows from operating activities during Fiscal 2023 and positive free cash flows during calendar 2023.
https://seekingalpha.com/news/3911764-organigram-reports-q4-results-issues-fy23-soft-guidance?mailingid=29829239&messageid=2900&serial=29829239.64&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=29829239.64
European countries now queuing up behind Germany to legalise cannabis in Europe.
Switzerland:
https://businesscann.com/switzerland-could-well-become-the-second-european-country-after-germany-to-legalise-recreational-cannabis/?mc_cid=bb0b14d701&mc_eid=322e52e758
Czech Republic:
https://www.dw.com/en/czech-republic-on-the-way-to-legalizing-cannabis/a-63616450?mc_cid=bb0b14d701&mc_eid=322e52e758
And the rest of Europe....?
"...the ‘green wave’, the cannabis sector is undeniably on the rise across Europe, with policy changes in both the medicinal and recreational spheres..."
https://volteface.me/recreational-cannabis-legalisation-in-europe/
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Tilray Stockholders Vote “FOR” Tilray’s Proposal to Protect Stockholders and Promote Accountability
Tilray Urges Stockholders to Vote Today to Help Modernize the Company’s Corporate Governance by Eliminating Super-Voting Stock
NEW YORK and LEAMINGTON, Ontario, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced that Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis), both leading independent providers of proxy research and vote recommendations to the investment community, have recommended that Tilray stockholders vote “FOR” Proposal 3, the Company’s proposal to eliminate Tilray’s Class 1 common stock at the Company’s Annual Meeting of Stockholders (the “Annual Meeting”) to be held on November 22, 2022.
“We are pleased that ISS and Glass Lewis agree that stockholders should support Proposal 3 at the upcoming Annual Meeting,” said Irwin D. Simon, Tilray Brands’ Chairman and Chief Executive Officer. “The endorsement of the two major independent proxy advisory firms reaffirms our conviction that Proposal 3 is in the best interests of our stockholders and a critical part of our strategy to simplify our capital structure and modernize our corporate governance, which we believe will protect stockholders and promote accountability. We encourage stockholders to vote “FOR” Proposal 3 and all proposals at our upcoming Annual Meeting to support strong corporate governance and oversight.”
In determining to recommend “FOR” Proposal 3, ISS noted1:
“This proposal will simplify and update the company's governing documents to reflect that no shares of Class 1 common stock are outstanding, and none will be issued in the future. In addition, this will have no impact on the rights of current shareholders. Therefore, support for this proposal is warranted.”
Glass Lewis, which joined ISS in recommending “FOR” Proposal 3, noted1:
“Allowing one vote per share generally operates as a safeguard for common shareholders by ensuring that those who hold a significant minority of shares are able to weigh in on issues set forth by the board.”
Tilray urges shareholders to vote today to support these key initiatives to ensure best corporate governance practices and help the Company protect the influence of its stockholders. Your support is important, no matter how many or how few shares you own.
If you have any questions, or need any assistance in voting your shares, please contact Morrow Sodali LLC at (800) 449-0910 toll-free in the U.S. and Canada or (203) 658-9400 or by email at TLRY@info.morrowsodali.com.
HELP TILRAY GROW!
VOTE “FOR” TODAY!
You could be right, Nick, and what a huge market to be in.... according to High Times:
https://hightimes.com/business/legislative-report-projects-72-billion-cannabis-industry-by-2030/
"A new legislative report delivered to Maryland lawmakers this week projects that the nationwide market for legal cannabis could climb to $72 billion per year by 2030, more than double the current market estimation of $32 billion annually...."
hahahaha....
Killazilla, you have value in your words... On a happy note: It is encouraging that the Rs and Ds are peacefully working together on cannabis laws... without doubt this is a healing plant... pity someone wouldn't give Putin a toke...
More good news...
Senate Majority Leader Chuck Schumer on Sunday said that the Senate is very close to agreeing on legislation that would allow cannabis businesses access to the US banking system based on discussions with some Republican senators.
"I am working in a bipartisan way with Democrats and Republicans to take the SAFE Banking Act, which allows financial institutions to involve themselves in cannabis companies and lend money to them—but it also does some things for justice, such as expunging a record," Schumer said Sunday evening in a televised debated with Republican challenger Joe Pinion.
The legislation that Schumer is talking about is similar to the SAFE Banking Plus legislation that has been floated around. It includes both banking reform and marijuana conviction expungements.
However, this legislation is unlikely to include language related to federal marijuana legalization, according to Marijuana Moment.
https://seekingalpha.com/news/3897904-schumer-says-getting-very-close-to-passing-marijuana-banking-bill-in-senate?mailingid=29546610&messageid=2900&serial=29546610.14563&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=29546610.14563
Senate Majority Leader Chuck Schumer on Sunday said that the Senate is very close to agreeing on legislation that would allow cannabis businesses access to the US banking system based on discussions with some Republican senators.
"I am working in a bipartisan way with Democrats and Republicans to take the SAFE Banking Act, which allows financial institutions to involve themselves in cannabis companies and lend money to them—but it also does some things for justice, such as expunging a record," Schumer said Sunday evening in a televised debated with Republican challenger Joe Pinion.
The legislation that Schumer is talking about is similar to the SAFE Banking Plus legislation that has been floated around. It includes both banking reform and marijuana conviction expungements.
However, this legislation is unlikely to include language related to federal marijuana legalization, according to Marijuana Moment.
https://seekingalpha.com/news/3897904-schumer-says-getting-very-close-to-passing-marijuana-banking-bill-in-senate?mailingid=29546610&messageid=2900&serial=29546610.14563&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=29546610.14563
Senate Majority Leader Chuck Schumer on Sunday said that the Senate is very close to agreeing on legislation that would allow cannabis businesses access to the US banking system based on discussions with some Republican senators.
"I am working in a bipartisan way with Democrats and Republicans to take the SAFE Banking Act, which allows financial institutions to involve themselves in cannabis companies and lend money to them—but it also does some things for justice, such as expunging a record," Schumer said Sunday evening in a televised debated with Republican challenger Joe Pinion.
The legislation that Schumer is talking about is similar to the SAFE Banking Plus legislation that has been floated around. It includes both banking reform and marijuana conviction expungements.
However, this legislation is unlikely to include language related to federal marijuana legalization, according to Marijuana Moment.
Most of the major cannabis multi-state operators are up on Schumer's comments in Monday trading.
Multi-state operators: Cresco Labs (OTCQX:CRLBF); Columbia Care (OTCQX:CCHWF); Trulieve Cannabis (OTCQX:TCNNF); Green Thumb Industries (OTCQX:GTBIF); Curaleaf Holdings (OTCPK:CURLF); MedMen Enterprises (OTCQB:MMNFF); Acreage Holdings (OTCQX:ACRHF); Ayr Wellness (OTCQX:AYRWF); Verano Holdings (OTCQX:VRNOF); and Jushi Holdings (OTCQX:JUSHF).
Cannabis-related ETFs: AdvisorShares Pure Cannabis ETF (YOLO), Amplify Seymour Cannabis ETF (CNBS), ETFMG Alternative Harvest ETF (NYSEARCA:MJ), AdvisorShares Pure US Cannabis ETF (MSOS), and Global X Cannabis ETF (POTX).
Cannabis stocks recently got a boost in the wake of Canopy Growth's (CGC) acquisition of Acreage Holdings (OTCQX:ACRHF).
https://seekingalpha.com/news/3897904-schumer-says-getting-very-close-to-passing-marijuana-banking-bill-in-senate?mailingid=29546610&messageid=2900&serial=29546610.14563&utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=29546610.14563
OrganiGram Holdings Inc. (NASDAQ:OGI) is expected to deliver revenue generation and free cash flow growth. Management announced that new products will be announced in the rest of 2022. Besides, with cash in hand, I would be expecting that more M&A activity would enhance revenue, and bring economies of scale. Even considering risks from further regulatory pressure around the cannabis industry and inflationary pressures, I believe that the current stock is considerably undervalued....
https://seekingalpha.com/article/4550830-organigram-undervalued-and-with-new-brands-in-the-pipeline?mailingid=29535899&messageid=2800&serial=29535899.1633&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=29535899.1633
thanks, Hunch.... and now for more good news....
OrganiGram Holdings: Undervalued And With New Brands In The Pipeline
Summary
OrganiGram is a medical cannabis provider as well as a seller of cannabis to adult recreational consumers.
Expectations from analysts are quite beneficial.
According to analysts, net sales growth in 2022 would reach 80%, 33% in 2023, and 28% in 2024.
In my view, OrganiGram has a significant amount of expertise in the M&A markets. Future transactions may help the company maintain its revenue growth.
https://seekingalpha.com/article/4550830-organigram-undervalued-and-with-new-brands-in-the-pipeline?mailingid=29535899&messageid=2800&serial=29535899.1633&utm_campaign=rta-stock-article&utm_medium=email&utm_source=seeking_alpha&utm_term=29535899.1633
Germany announces plan to legalise cannabis for recreational use
Minister says legalisation could set precedent for rest of Europe, though plan is still subject to EU approval
https://www.theguardian.com/world/2022/oct/26/germany-to-legalise-cannabis-for-recreational-use
( population of Germany: 83.13 million
population of EU: 447 million )
https://www.theguardian.com/world/2022/oct/26/germany-to-legalise-cannabis-for-recreational-use
Germany announces plan to legalise cannabis for recreational use
Minister says legalisation could set precedent for rest of Europe, though plan is still subject to EU approval
I am not smart enough to explain....
HOWEVER, Baz...
Germany unveils plans to legalise cannabis
Move would create the world’s largest regulated national market for the drug
https://www.ft.com/content/ac495141-4270-454f-a5aa-53a9f2152baf
The German government has unveiled a detailed framework for the legalisation of cannabis, setting the country on course to becoming the world’s largest regulated national market for the drug.
“Drug policy has to be updated,” said health minister Karl Lauterbach on Wednesday, citing unchecked rising consumption of cannabis among young adults, and an increasing threat to public health from impure and high-strength products as reasons behind the proposed change.
Before becoming law, the proposals will face an extensive legal consultation with European neighbours and will then will be put in front of German lawmakers in the Bundestag.
Lauterbach said while the package could be seen as “the most liberal cannabis legalisation project in Europe”, its purpose was to increase, not decrease, public oversight. The proposals would create “the most strictly regulated [cannabis] market in Europe, with the clear objective of decriminalisation and improving protections for young people and public health,” he said.
The German government’s proposals follow the decision by US president Joe Biden to pardon thousands of Americans convicted of possessing the drug. “Too many lives have been upended because of our failed approach to marijuana,” Biden said earlier this month in a move seen by many as a prelude to a liberalisation of US law.
Around 4mn Germans took illegal cannabis products last year, and a quarter of all 18-24 year olds, according to the ministry of health.
Berlin’s planned liberalisation will not be straightforward. Germany, as a member of Europe’s border-check free Schengen Zone, will need to overcome what are likely to be strong objections from fellow EU states.
Regulations prohibit the import of illegal drugs over European borders, meaning the country will have to prove it can tightly monitor border crossings and not undermine its neighbours’ own narcotics policies.
Negotiations to find a consensus among Schengen member states are meanwhile unlikely to be a high diplomatic priority, given Europe’s current geopolitical agenda.
Germany unveils plans to legalise cannabis
Move would create the world’s largest regulated national market for the drug
https://www.ft.com/content/ac495141-4270-454f-a5aa-53a9f2152baf
The German government has unveiled a detailed framework for the legalisation of cannabis, setting the country on course to becoming the world’s largest regulated national market for the drug.
“Drug policy has to be updated,” said health minister Karl Lauterbach on Wednesday, citing unchecked rising consumption of cannabis among young adults, and an increasing threat to public health from impure and high-strength products as reasons behind the proposed change.
Before becoming law, the proposals will face an extensive legal consultation with European neighbours and will then will be put in front of German lawmakers in the Bundestag.
Lauterbach said while the package could be seen as “the most liberal cannabis legalisation project in Europe”, its purpose was to increase, not decrease, public oversight. The proposals would create “the most strictly regulated [cannabis] market in Europe, with the clear objective of decriminalisation and improving protections for young people and public health,” he said.
The German government’s proposals follow the decision by US president Joe Biden to pardon thousands of Americans convicted of possessing the drug. “Too many lives have been upended because of our failed approach to marijuana,” Biden said earlier this month in a move seen by many as a prelude to a liberalisation of US law.
Around 4mn Germans took illegal cannabis products last year, and a quarter of all 18-24 year olds, according to the ministry of health.
Berlin’s planned liberalisation will not be straightforward. Germany, as a member of Europe’s border-check free Schengen Zone, will need to overcome what are likely to be strong objections from fellow EU states.
Regulations prohibit the import of illegal drugs over European borders, meaning the country will have to prove it can tightly monitor border crossings and not undermine its neighbours’ own narcotics policies.
Negotiations to find a consensus among Schengen member states are meanwhile unlikely to be a high diplomatic priority, given Europe’s current geopolitical agenda.
great news... about time Canadian canna managements found the bottle to take the battle directly to the home of the free...
thanks, BB, yesterday was some spike, however, today the shorts are spending their wealth to stop this incoming-tide...
Hi Stoner, hopes you are good form.... and hopes that that Stoney Joe doesn't upset you too much.... as far as I can see US politicians (Rs&Ds) are way behind what their constituents want regarding canna, while Central Europe politicians are now collectively running to catch up with their constituents who are demanding commercial legalisation... I believe Germany will be legal in '23 / '24 and vast sway of Europe by '25 / '26...
An intriguing point you raise about guns... only in America, eh....
A question: will descheduling cannabis in the U.S. mean that Canadian canna companies could start selling cannabis in the U.S.....?
Let's go Smokey Joe....
Let's go Smokey Joe....
Tilray: Sentiment Could Be A Catalyst For An Aggressive Price Appreciation
Tilray stock surged almost 40% after following the announcement that the Biden administration took a major step towards the legalization of marijuana.
On October 6th, Biden announced that he will pardon all federal marijuana possession convictions, as well as all respective convictions in Washington D.C.
Tilray stock quickly became the most discussed stock on social media, and sentiment could be a catalyst for an aggressive price appreciation.
In my opinion, Tilray's 40% price jump could have further room to go.
I advise to buy the 125/200 percent moneyness call spreads (short $8 strike, long $5 strike) with about 10 weeks to expiration.
https://seekingalpha.com/article/4545210-tilray-sentiment-catalyst-price-appreciation
hopefully this is another mega run... money making time coming up for old hands and newbies... hopefully a canna bill gets attached to some US end of term legislation... and hey bingo... let's go Smokey Joe....
Tilray Brands’ First Quarter Fiscal Year 2023 Performance Affirms Global Cannabis Leadership
October 7, 2022 at 7:00 AM EDT
https://tilray.gcs-web.com/news-releases/news-release-details/tilray-brands-first-quarter-fiscal-year-2023-performance-affirms
Reported Net Revenue at $153.2 Million; On a Constant Currency Basis, Net Revenue Remained Strong at $166.5 Million
Cannabis Gross Margin Increased to 51% from 43% in the Prior Year Quarter
Delivered $108 Million in Annualized Cash Savings to Date, Expects to Deliver $130 Million Across Corporate Optimization Plans
Second Highest Adjusted EBITDA in Company’s History Marking the 14th Consecutive Quarter of Positive Adjusted EBITDA
Strong Balance Sheet with ~$500 Million in Cash
Company Reconfirms Guidance to Generate $70-$80 Million of Adjusted EBITDA and be Free-Cash Flow Positive in Its Operating Business Units this Fiscal Year
Tilray Brands Maintains #1 Cannabis Market Share in Canada and Germany
LEAMINGTON, Ontario and NEW YORK, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life, today reported financial results for the first fiscal quarter ended August 31, 2022. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Financial Highlights – First Quarter Fiscal 2023
Reported net revenue was $153.2 million. On a constant currency basis, net revenue remained strong at $166.5 million for the quarter.
Maintained #1 position in Canada with 8.5% cannabis market share, driven by Tilray’s comprehensive portfolio of adult-use brands.
International cannabis revenue was $10.4 million. On a constant currency basis, international cannabis revenue was $11.9 million.
Achieved $108 million in annualized cash cost-savings since the closing of the Tilray – Aphria transaction in May 2021, up from $85 million as of May 31, 2022.
Net loss was $66 million. Adjusted EBITDA of $13.5 million, marking the 14th consecutive quarter of positive adjusted EBITDA and second highest achieved in the Company’s history.
Tilray – First Quarter 2023 Earnings Call
Oct 7, 2022 at 8:30 AM EDT
Listen to webcast
https://viavid.webcasts.com/viewer/event.jsp?ei=1566597&tp_key=02f3694fdf
Cannabis company Canopy applauds Biden’s marijuana pardons as stock surges
Canopy Growth Corporation shares jumped 22% Thursday after President Joe Biden announced he’ll pardon thousands of people for federal marijuana offenses.
The Canada-based cannabis company applauded Biden’s decision.
https://www.cnbc.com/2022/10/06/cannabis-company-canopy-applauds-biden-marijuana-pardons-stock-surges.html
Canopy Growth applauded President Joe Biden’s announcement Thursday that he will pardon thousands of people convicted of marijuana possession.
“Today represents action from the Administration that we have been waiting for – an acknowledgement that cannabis prohibition has failed and that too many lives have been significantly impacted as a result,” David Culver, vice president of government relations Canopy, said in a statement.
Shares of the Canadian-based cannabis company, the world’s largest, jumped 22% after the news, closing at $3.75. Shares of fellow cannabis firm Tilray Brands
gained over 30%. Tilray couldn’t be reached for comment by CNBC.
“President Biden, in keeping with his campaign commitments, has set into motion the actions needed to heal the harms of the past and chart a course for responsible, legal cannabis markets in the future,” Culver said.
".... the immediate reaction in the publicly traded cannabis market was one of excitement, with most stocks getting a significant boost in trading following the news...."
https://mjbizdaily.com/biden-announcement-on-marijuana-scheduling-and-pardons-could-alter-face-of-the-industry
".... the immediate reaction in the publicly traded cannabis market was one of excitement, with most stocks getting a significant boost in trading following the news...."
https://mjbizdaily.com/biden-announcement-on-marijuana-scheduling-and-pardons-could-alter-face-of-the-industry
Biden asks agencies to review marijuana’s classification, pardons prior federal-possession offenses
Cannabis stocks rally on announcement
https://www.marketwatch.com/story/biden-asks-agencies-to-review-marijuanas-classification-pardons-prior-federal-possession-offenses-11665084331?mod=home-page
Biden to pardon thousands for ‘simple possession’ of marijuana
US president also calls for review of drug’s classification under federal law
https://www.ft.com/content/f08d1bc2-467f-44e2-bf29-16c2c2ee72c0